Tamer Sallam is a Cardiology physician affiliated with University of California, Los Angeles. OpenAlex indexes 86 publications with 3,524 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
650 Charles E Young Dr S # A2-237
Los Angeles, CA 900958347
Telephone
310-267-5868Provider last certified this registry record 5 Mar 2021.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Travere Therapeutics, Inc.Program year20221 payment
- Regeneron Healthcare Solutions, Inc.Program year20211 payment
- Travere Therapeutics, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
95.4%PCSK9 Inhibitor31.9%Repatha Sureclick66%Praluent Pen28%Repatha Pushtronex6%Part D<11 patientsStatin15.7%Rosuvastatin Calcium49%Pravastatin Sodium29%Atorvastatin Calcium21%Part D<11 patients+ 8 more classes in this area
Blood & clotting
2.4%Factor Xa inhibitor2.4%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
2.2%GLP-1 receptor agonist2.2%Ozempic100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
9 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- NIDDK HERITAGE: Harnessing Tandem Repeats in Multi-Ancestry Metabolic Gene-Phenotype Relationships
University of California Los Angeles
FY2026$1,581,254RC2DK144739 - Hidden Layers of RNA Regulation in Inflammation, Lipid Metabolism, and Atherosclerosis
University of California Los Angeles
FY2026$1,564,296R01HL185164 - Alternative Polyadenylation in Cardiovascular Disease
University of California Los Angeles
FY2026$1,560,215R01HL180397
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”